Skip to search formSkip to main contentSkip to account menu

Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

A large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas, providing the largest available set of microarray data with extensive pathological and clinical annotation for lungAdenocARCinomas.
View on Nature (opens in a new tab)

Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

The addition of oxaliplatin to weekly FULV significantly improved DFS in patients with stage II and III colon cancer, and FLOX can be recommended as an effective option in clinical practice.
View on PubMed (opens in a new tab)

Clinical trial designs for predictive marker validation in cancer treatment trials.

The major issues to consider when designing a clinical trial assessing the usefulness of a predictive marker are reviewed and two classes of clinical trial designs are presented: the Marker by Treatment Interaction Design and the Marking-Based Strategy Design.
View on PubMed (opens in a new tab)

Vascular Injury Induces Expression of Periostin: Implications for Vascular Cell Differentiation and Migration

Periostin expression is associated with smooth muscle cell differentiation in vitro and promotes cell migration in rat carotid arteries after balloon injury and may be useful in discriminating smooth muscle and fibroblast lineages.
View on Wolters Kluwer (opens in a new tab)

Prognostic factors in colorectal cancer

This work states that the current state of knowledge regarding pathologic prognostic factors (factors linked to outcome) and predictive models for disease prediction are inadequate and need to be improved.

Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.

It is shown that the prolongation in median survival between two arms of a randomized study was rarely in excess of 2 months, and techniques for improved use of patient resources and appropriate trial design for phase III randomized therapeutic trials with patients with advanced NSCLC need to be developed.
View on PubMed (opens in a new tab)

Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.

The findings indicate that under properly controlled conditions it is feasible to perform complete tumor microarray analysis, from tissue processing to hybridization and scanning, at multiple independent laboratories for a single study.
View on PubMed (opens in a new tab)

Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.

Because peak plasma concentrations near those effective in vitro (0.5-1 mM) were achieved, but butyrate disappeared from plasma by 5 h after dose, this work is pursuing dose escalation with dosing three times daily, beginning at a dose of 450 mg/kg/day.
View on PubMed (opens in a new tab)

Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

This is the first trial that evaluated single-agent, low-dose cyclophosphamide in HGSOC, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers and it was well tolerated and clinical activity was observed.
View on Publisher (opens in a new tab)

Endoglin Structure and Function

It is suggested that ALK1 is a preferred TGFβ receptor kinase for endoglin threonine phosphorylation in HUVECs and a role forendoglin phosphorylated in the regulation of endothelial cell adhesion and growth by ALK2 is indicated.
View on Publisher (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)